Piper Sandler Maintains Overweight on ALX Oncology Holdings, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowered the price target from $48 to $8.
August 11, 2023 | 4:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on ALX Oncology Holdings but lowered the price target from $48 to $8.
The news is directly related to ALX Oncology Holdings and is likely to have a negative impact on its stock price in the short term. The lowering of the price target from $48 to $8 by Piper Sandler indicates a significant decrease in the expected value of the stock, which could lead to selling pressure.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100